New Three-Drug cocktail aims to beat back aggressive leukemia before transplant
NCT ID NCT06483906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a three-drug combination (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant in 56 adults aged 18-55 with newly diagnosed, intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach improves survival and reduces the chance of the cancer coming back. Participants receive up to four cycles of the drug combo before transplant, with close monitoring for side effects and disease response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax, azacitidine, and homoharringtonine (VAH regimen)
- What this could lead to
- If successful, this combination could offer a more effective way to control aggressive AML and improve long-term survival after a stem cell transplant.
- What could go wrong
- This is a small, early-phase trial (56 people) with no comparison group. The treatment involves strong chemotherapy and a transplant, which carry serious risks like infection and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General hospital,Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?